Category: isoxazole

Lin, Jiunn-Chang published the artcilePERK/ATF4-dependent ZFAS1 upregulation is associated with sorafenib resistance in hepatocellular carcinoma cells, Application In Synthesis of 2323027-38-7, the publication is International Journal of Molecular Sciences (2021), 22(11), 5848, database is CAplus and MEDLINE.

Sorafenib, a multi-kinase inhibitor, is the first-line treatment for advanced hepatocellular carcinoma (HCC) patients. However, this drug only provides a short improvement of patients’ overall survival, and drug resistance is commonly developed. Thus, the identification of resistant factor(s) or biomarker(s) is needed to develop more efficient therapeutic strategies. Long, non-coding RNAs (lncRNAs) have recently been viewed as attractive cancer biomarkers and drive many important cancer phenotypes. A lncRNA, ZFAS1 (ZNFX1 antisense RNA 1) has been found to promote HCC metastasis. This study found that sorafenib induced ZFAS1 expression specifically in sorafenib-resistant HCC cells. Although ZFAS1 knockdown did not restore the sensitivity of HCC cells to sorafenib, its expression may act as a resistant biomarker for sorafenib therapy. Bioinformatics anal. predicted that sorafenib tended to induce pathways related to endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) in sorafenib-resistant HCC cells. In vitro exptl. evidence suggested that sorafenib induced protein kinase RNA-like ER kinase (PERK)/activating transcription factor 4 (ATF4)-dependent ZFAS1 expression, and sorafenib resistance could be overcome by PERK/ATF inhibitors. Therefore, PERK/ATF4/ZFAS1 signaling axis might be an attractive therapeutic and prognostic biomarker for sorafenib therapy in HCC.

International Journal of Molecular Sciences published new progress about 2323027-38-7. 2323027-38-7 belongs to isoxazole, auxiliary class Metabolic Enzyme,ATF/CREB proteins, name is N-(1-(2,4-Bis(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-5-(furan-2-yl)isoxazole-3-carboxamide, and the molecular formula is C20H12F6N4O3, Application In Synthesis of 2323027-38-7.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Li, Jian-yu published the artcileEffects of dexmedetomidine on postoperative mechanical pain threshold in patients undergoing laparoscopic cholecystectomy under continuous infusion of remifentanil, Quality Control of 198470-85-8, the publication is Shiyong Yixue Zazhi (2015), 31(21), 3574-3577, database is CAplus.

This paper is to identify whether dexmedetomidine can prevent postoperative hyperalgesia of patients undergoing laparoscopic cholecystectomy. One hundred and twenty patients undergoing elective laparoscopic cholecystectomy were randomly divided into three groups: dexmedetomidine group (group D, patients receiving dexmedetomidine), parecoxib sodium group (group P, patients receiving parecoxib sodium) and control group (group C). Mech. pain thresholds on periincisional area and VAS score were recorded 2, 4, 8, 12, 24, 48 h after surgery. Mech. pain thresholds in group C at 2, 4, 8, 12, 24, 48 h after operation decreased significantly compared with those before operation(P<0.01) but those in group D had no significant difference, and the thresholds in group P at 4 h, 8 h had no significant decrease. Compared with those in group C, mech. pain thresholds in group D increased at 2, 4, 8, 12, 24, 48 h after operation(P<0.05), and those in group P increased at 4 h and 8 h after operation(P<0.05). Compared with those in group P, mech. pain thresholds in group D increased at 12, 24, 48 h after operation. Compared with preoperative VAS values, values were significantly increased in every group(P<0.05). Furthermore, postoperative VAS values had no correlation with mech. pain threshold in each group and the incidence of adverse reactions had no significant difference among three groups(P>0.05). Dexmedetomidine can prevent postoperative hyperalgesia in patients undergoing laparoscopic cholecystectomy.

Shiyong Yixue Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Quality Control of 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Liang, Hong-Wen published the artcileAtom-Economic Silver-Catalyzed Difunctionalization of the Isocyano Group with Cyclic Oximes: Towards Pyrimidinediones, SDS of cas: 1076-59-1, the publication is Angewandte Chemie, International Edition (2018), 57(20), 5720-5724, database is CAplus and MEDLINE.

An unprecedented silver-catalyzed difunctionalization of the isocyano group with cyclic oximes is described. This method allows efficient and atom-economic assembly of a vast array of structurally novel and interesting pyrimidinediones, and tolerates a range of functionalities. The resulting products can be easily converted into some useful compounds Furthermore, the method can also be applied for the late-stage modification of a few biol. active mols.

Angewandte Chemie, International Edition published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C9H7NO2, SDS of cas: 1076-59-1.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Fu, Weihua published the artcileEfficacy and Safety of Parecoxib/Phloroglucinol Combination Therapy Versus Parecoxib Monotherapy for Acute Renal Colic: A Randomized, Double-Blind Clinical Trial, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, the publication is Cell Biochemistry and Biophysics (2014), 69(1), 157-161, database is CAplus and MEDLINE.

To investigate whether the addition of phloroglucinol to parecoxib could improve the efficacy in patients with acute renal colic. Patients of acute renal colic were randomly allocated to receive i.v. Parecoxib 40 mg plus placebo or Parecoxib 40 mg plus phloroglucinol 80 mg, resp. Pain intensity was recorded using a visual analog scale (VAS) before drug administration and 5, 15, 30, 60, and 120 min after treatment start. The primary outcome was the mean pain intensity difference (PID) at each checkpoint and the effectiveness of drugs (≥50 ^decrease in VAS score at the end checkpoint). The need for rescue analgesics and the incidence of adverse effects were considered as secondary outcome of the study. Among 236 patients enrolled in the study, 119 patients received i.v. parecoxib plus placebo and 114 patients received i.v. parecoxib plus phloroglucinol, the remaining 3 patients given up treatment. Baseline demographics were similar between two groups. There are significant differences in the PID at 15 and 30 min between two groups (P_15 min = 0.011, P_30 min = 0.013). Rescue analgesics were required by 17 patients (14.3 )̂ receiving parecoxib, 7 patients (6.1 )̂ receiving parecoxib plus phloroglucinol (P = 0.041). There were no differences in PID at other checkpoints between two groups, as well as in the incidence of adverse events and the drug effectiveness. Parecoxib in combination with phloroglucinol for acute renal colic has a faster action, also reduces the demand of rescue analgesics.

Cell Biochemistry and Biophysics published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, Recommanded Product: Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Zhu, Yang-Zi published the artcileParecoxib prevents early postoperative cognitive dysfunction in elderly patients undergoing total knee arthroplasty: A double-blind, randomized clinical consort study, Product Details of C19H17N2NaO4S, the publication is Medicine (Philadelphia, PA, United States) (2016), 95(28), e4082, database is CAplus and MEDLINE.

Background: Trial design neuroinflammation and postoperative pain after surgery are increasingly reported in association with postoperative cognitive dysfunction (POCD). Parecoxib, a selective cyclooxygenase (COX)-2 inhibitor, is used for postoperative analgesia for its potent anti-inflammatory and analgesic effects. This study aimed to evaluate parecoxib’s effects on POCD in elderly patients undergoing total knee arthroplasty. Methods: Around 134 elderly patients undergoing total knee arthroplasty were randomly divided into parecoxib (group P) and control (groupC) groups, and treated with parecoxib sodium and saline, resp., shortly after induction of general anesthesia and 12-h postsurgery, resp. Perioperative plasma IL-1β, IL-6, TNF-α, and C-reactive protein (CRP) levels were measured. Postoperative pain was assessed following surgery. Neuropsychol. tests were performed before surgery, and 1 wk and 3 mo postoperation. Results: POCD incidence in group P was significantly lower compared with that of group C at 1 wk after surgery (16.7% vs 33.9%; P<0.05); no significant difference was found between groups C and P at 3-mo follow-up (9.7% vs 6.7%). Compared with group C values, visual analog pain scale (VAS) scores at 3, 6, and 12h after surgery were significantly lower in group P(P<0.05). Plasma IL-1β, IL-6, and TNF-α levels were lower in group P than in group C after the operation (P<0.05). No significant difference in the plasma CRP level was found between groups P and C. Conclusions: Parecoxib sodium decreases POCD incidence after total knee arthroplasty in elderly patients and may explain how this drug suppresses inflammation and acute postoperative pain caused by surgical trauma.

Medicine (Philadelphia, PA, United States) published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C38H74Cl2N2O4, Product Details of C19H17N2NaO4S.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Huang, Xuelian published the artcileAnalysis of effect of levobupivacaine combined with tramadol on infiltration anesthetic analgesia of incision after lumbar intervertebral disc surgery, SDS of cas: 198470-85-8, the publication is Fujian Yiyao Zazhi (2015), 37(4), 111-113, database is CAplus.

Objective: To analyze effect of evobupivacaine combined with tramadol on infiltration anesthetic analgesia of incision after lumbar intervertebral disk surgery. Methods: 60 patients who were going to being subjected to lumbar intervertebral disk surgery were randomly divided into 3 groups, evobupivacaine plug tramadol group (A group), evobupivacaine group (B group) and evobupivacaine plug physiol. saline group (C group). The patients in the three groups were given corresponding anesthetic analgesia treatment, resp. If VAS scores of the patients were higher than 3, the patients were given pethidine, and VAS scores and dosages of pethidine used 0 (T₀), 2 (T₂), 4 (T₄), 8 (T₈), 12 (T₁₂) and 24 (T₂₄) h after the surgery were recorded. If VAS cores were greater than 5, the patients were given parecoxib sodium, and the time when parecoxib sodium was used and dosage of parecoxib sodium were recorded. Results: Within 24 h after the surgery, there were 3, 7 and 10 cases of nausea in the groups A, B and C, resp., there were 1, 4, and 4 cases vomiting in the groups A, B and C, resp., and no skin pruritus complication occurred in the three groups. No patient in the A group used parecoxib sodium, 3 patients in the B groups used parecoxib sodium 2 h after the surgery, and all patients in the C group were given parecoxib sodium within 1 h after the surgery. No patient in the A group used PCA, the time when the B group used PAC was (147.0 ± 167.3) min after the surgery, that in the C group was (13.6 ± 8.7) min after the surgery, and the difference was statistically significant (P < 0.05). No patient in the A group used pethidine, total dosage of pethidine used in the B group was (138.0 ± 76.2) mg, total dosage of pethidine used in the B group was (183.2 ± 86.3) mg, and the difference was statistically significant (P < 0.05). Compared with the group C, VAS core at the time point of T₀ in the groups A and B were statistically significant (P < 0.05). At the time points of T₂, T₄, T₈ and T₁₂, VAS scores of the group A were statistically significantly different from those of the group C. Conclusion: For the patients underwent lumbar intervertebral disk excision, levobupivacaine combined with tramadol for infiltration anesthesia of incision has better postoperative analgesia effect, causes lower VAS cores, and reduces use of opioid drugs. Combination of the two drugs is safe and effective, and is worthy of wide application.

Fujian Yiyao Zazhi published new progress about 198470-85-8. 198470-85-8 belongs to isoxazole, auxiliary class Immunology/Inflammation,COX, name is Sodium ((4-(5-methyl-3-phenylisoxazol-4-yl)phenyl)sulfonyl)(propionyl)amide, and the molecular formula is C19H17N2NaO4S, SDS of cas: 198470-85-8.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Nakayama, Yuji published the artcileAn Efficient Synthesis of N-(Hetero)arylcarbazoles: Palladium-Catalyzed Coupling Reaction between (Hetero)aryl Chlorides and N-Carbazolylmagnesium Chloride, Quality Control of 57103-14-7, the publication is Advanced Synthesis & Catalysis (2015), 357(10), 2322-2330, database is CAplus.

An efficient method for the synthesis of N-(hetero)arylcarbazoles, useful compounds for functional materials, was reported. Various (hetero)aryl chlorides reacted with N-carbazolylmagnesium chloride in the presence of a palladium catalyst (0.05 to 0.2 mol%) prepared from allylpalladium(II) chloride dimer {[PdCl(allyl)]₂} and di-tert-butyl(2,2-diphenyl-1-methylcyclopropan-1-yl)phosphine (cBRIDP) under mild conditions (110°) in a short period of time (15 min. to 2 h) to give N-(hetero)arylcarbazoles in high yields. The reactions of bromochlorobenzenes proceeded in favor of the bromo group to afford N-(chlorophenyl)carbazoles in a highly selective manner. Functional materials for use in organic light-emitting diodes, such as 1,3-bis(9H-carbazol-9-yl)benzene, 2,6-bis(9H-carbazol-9-yl)pyridine, 4,4′-bis(9H-carbazol-9-yl)biphenyl and 1,3,5-tris(9H-carbazol-9-yl)benzene, were also obtained in high yields within 15 min. by the reaction of (hetero)aryl polyhalides. Optimization of the reaction conditions and a postulated catalytic cycle for the reaction were also discussed.

Advanced Synthesis & Catalysis published new progress about 57103-14-7. 57103-14-7 belongs to isoxazole, auxiliary class Fused Tricycles,Carbazoles, name is 9-(4-Fluorophenyl)-9H-carbazole, and the molecular formula is C18H12FN, Quality Control of 57103-14-7.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Nogi, Keisuke published the artcileAromatic metamorphosis: conversion of an aromatic skeleton into a different ring system, Product Details of C18H12FN, the publication is Chemical Communications (Cambridge, United Kingdom) (2017), 53(29), 4055-4065, database is CAplus and MEDLINE.

Recent advances in the area of “aromatic metamorphosis”, where various aromatic compounds, such as dibenzothiophenes, dibenzofurans, and benzofurans, are transformed into a variety of ring systems using a multi-step strategy or ideally in one step has been reviewed.

Chemical Communications (Cambridge, United Kingdom) published new progress about 57103-14-7. 57103-14-7 belongs to isoxazole, auxiliary class Fused Tricycles,Carbazoles, name is 9-(4-Fluorophenyl)-9H-carbazole, and the molecular formula is C18H12FN, Product Details of C18H12FN.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Guo, Fenglou published the artcileTransition-Metal-Free N-Arylation of Carbazoles and C-Arylation of Tetrahydrocarbazoles by using Diaryliodonium Salts, Category: isoxazole, the publication is Asian Journal of Organic Chemistry (2012), 1(3), 218-221, database is CAplus.

A method for the direct arylation of carbazole derivs, and C-arylation of tetrahydrocarbazole derivatives (substituted indole derivatives) with diaryliodonium salts mediated by potassium tert-butoxide (KOtBu) was developed. The feasibility of an alkynylation of tetrahydrocarbazole by this protocol was also demonstrated. The title compound thus formed was (phenylethynyl)-2,3,4,4a,9,9a-hexahydro-9H-carbazole derivative (I). The advantages of the present reaction include easy handling of this metal-free process. The application of this method to the manufacture of photoelec. functional materials is anticipated. The method may also be applied to the the synthesis of related alkaloids (no data). The synthesis of the target compounds was achieved using 9H-carbazole derivatives, 2,3,4,4a,9,9a-hexahydro-9H-carbazole and 1,2,3,3a,4,8b-hexahydrocyclopent[b]indole as starting materials and diphenyliodonium 1,1,1-trifluoromethanesulfonate (1:1) derivatives as arylation reactants. The title compounds thus formed included 9-phenyl-9H-carbazole derivatives

Asian Journal of Organic Chemistry published new progress about 57103-14-7. 57103-14-7 belongs to isoxazole, auxiliary class Fused Tricycles,Carbazoles, name is 9-(4-Fluorophenyl)-9H-carbazole, and the molecular formula is C18H12FN, Category: isoxazole.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem

Shen, Yao-Bin published the artcileHexafluoroisopropanol-Mediated Redox-Neutral α-C(sp³)-H Functionalization of Cyclic Amines via Hydride Transfer, SDS of cas: 1076-59-1, the publication is Journal of Organic Chemistry (2020), 85(4), 1915-1926, database is CAplus and MEDLINE.

Hexafluoroisopropanol has been demonstrated as the versatile promoter for redox-neutral α-C(sp³)-H functionalization of cyclic amines via the cascade [1,5]-hydride transfer/cyclization strategy. A wide range of cyclic amines are functionalized into bioactive tetrahydroquinolines, quinazolines, benzoxazines, and benzotriazepines in moderate to excellent yields. This protocol features additive-free conditions, operational simplicity, and wide substrate scope.

Journal of Organic Chemistry published new progress about 1076-59-1. 1076-59-1 belongs to isoxazole, auxiliary class Oxazoline,Benzene,Ester, name is 3-Phenylisoxazol-5(2H)-one, and the molecular formula is C14H14, SDS of cas: 1076-59-1.

Referemce:
https://en.wikipedia.org/wiki/Isoxazole,
Isoxazole | C3H3NO – PubChem